HRCI & SHRM Pre-Approved Crawford Advisors Webinar Series | Drug Deals: Understanding the Intricacies of PBM Contracts, Language and Opportunities

Posted July 17, 2017 by Megan DiMartino in Uncategorized | 0 comments

Pharmacy Benefit Management contracts are notorious for being confusing and vague, yet, extremely important. Join Crawford Advisors’ Director of Data Analytics, Scott Mayer, for this complimentary, one-hour, HRCI* and SHRM** pre-approved webinar as he discusses how PBM contracts can vary, even within the same PBM. With pharmacy spend now accounting for 20-25% of total healthcare spend, and growing, understanding these details has become more important than ever.

Topics include:

  • Contract Definitions
    • Generics
    • Single Source Medications
  • How to Determine Rebate Values
  • True Costs & Available Discounts
  • And More!

Webinar Details:

  • Thursday, July 27, 2017
  • 1:00 – 2:00pm EDT
  • No Cost to Attend
  • This webinar is open to all HR and Finance Professionals – but not to brokers, agents, TPAs and PEOs.

*The use of this seal confirms that this activity has met HR Certification Institute’s (HRCI) criteria for recertification credit pre-approval. This activity has been approved for 1 HR (General) recertification credit hours toward aPHR, PHR, PHRca, SPHR, GPHR, PHRi, and SPHRi recertification through HRCI.

**Crawford Advisors is recognized by SHRM to offer Professional Development Credits (PDCs) for SHRM-CP or SHRM-SCP. This program is valid for 1 PDC for the SHRM-CP or SHRM-SCP. For more information about certification or recertification, please visit shrmcertification.org.

For more information contact info@crawfordadvisors.com. The information contained in this post, and any attachments, is not intended and should not be misconstrued as legal advice. You should contact your employment, benefits or ERISA attorney for legal direction.

Share on Google+Share on LinkedInPin on PinterestShare on RedditShare on TumblrShare on FacebookTweet about this on Twitter
Tags: , , , , , , , , ,

Comments are closed.